author-photo

Pascal Minini

Regeneron

28

Papers

589

Citations

Citation Trend

Filter By

Papers (21) Sort By

Journal Conference Others

Safety, pharmacokinetics, and pharmacodynamics of oral venglustat in Parkinson disease patients with a GBA mutation from Japan and the rest of the world: Results from part 1 of the MOVES-PD study

2020 Molecular Genetics and Metabolism
Show All
- Source
- Cite
- Save
Citations (1)
Natural history of late-onset GM2 gangliosidosis: Four years of data collected at NTSAD annual conferences

2020 Molecular Genetics and Metabolism
Show All
- Source
- Cite
- Save
Citations (0)
Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials

2019 Atherosclerosis
Show All
- Source
- Cite
- Save
Citations (34)
SaO002QUANTITATIVE RELATIONSHIP BETWEEN TKV GROWTH RATE AND eGFR RATE OF DECLINE IN ADPKD PATIENTS

2019 Nephrology Dialysis Transplantation
Show All
- Source
- Cite
- Save
Citations (0)
Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia

2017 Coronary Artery Disease
Show All
- Source
- Cite
- Save
Citations (16)
Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program)

2017 American Journal of Cardiology
Show All
- Source
- Cite
- Save
Citations (93)
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia

2017 Journal of Clinical Lipidology
Show All
- Source
- Cite
- Save
Citations (41)
RELATIONSHIP BETWEEN MAJOR ADVERSE CARDIOVASCULAR EVENTS AND ACHIEVED LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS IN PHASE 3 ODYSSEY TRIALS OF ALIROCUMAB VERSUS CONTROL

2016 Journal of the American College of Cardiology
Show All
- Source
- Cite
- Save
Citations (2)
Reductions in Atherogenic Lipids and Major Cardiovascular EventsClinical Perspective

2016 Circulation
Show All
- Source
- Cite
- Save
Citations (0)
Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control.

2016 Circulation
Show All
- Source
- Cite
- Save
Citations (84)